Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947423 · ClinicalTrials.gov registry record · Phase 3
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
A Phase 3 study, sponsored by Repurposed Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT04947423: Completed Phase 3 study, sponsored by Repurposed Therapeutics.
NCT04947423 is a Phase 3 study that has completed, run by Repurposed Therapeutics. The registered enrollment target is 140 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04947423, a Phase 3 study, has completed, sponsored by Repurposed Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion
Primary Outcome
Participants who report no vomiting within 4 hours after receiving study drug and no use of rescue treatment (e.g., dimenhydrinate) within 4 hours after receiving study drug
Interventions
- DRUG Placebo
- DRUG DPI-386 Nasal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 3 |
What the finished NCT04947423 record still lists
NCT04947423 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04947423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04947423 about?
NCT04947423 is a clinical study titled "Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion". This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion
What is the current status of trial NCT04947423?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2021-06-14. Estimated completion is 2021-08-12.
What interventions are being tested in trial NCT04947423?
The interventions under investigation include: Placebo (DRUG), DPI-386 Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT04947423?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04947423's enrollment target sits among peer trials
140 1565th of 2000 higher than 424 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI